
Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
Hematologic Oncology Update
00:00
Xanu and Calabrutinib: A Comparison
I think I've seen some data on the tolerability of Xanu and patients who are intolerant of a Cala, not too much. What about the other way? Do you see patients who don't tolerate Xanu and do tolerate a Cala? Yeah, so Xanabrutin has the 215 study and that's looked at two cohorts. So with Ibruttinib and with a Calabrut inib intolerance, that then switched to Xanu. Calabruts does not have any really data from Xanu to a Cala. All three are good drugs, I think we can switch between all three. But as we're starting with second generation inhibitors
Transcript
Play full episode